|
Synonyms: MORAb-009
Compound class:
Antibody
Comment: Amatuximab is a chimeric monoclonal antibody to mesothelin (MSLN; Q13421), a cell surface glycoprotein highly expressed in malignant pleural mesothelioma, all pancreatic adenocarcinoma, the majority of ovarian adenocarcinoma, as well as in non-small cell lung and colorectal cancers[5].
The crystal structure of the Fab fragment of amatuximab in complex with a mesothelin fragment (amino acids 7-64) has been deposited in Protein Data Bank with accession 4F33 [4]. |
| No information available. |
Summary of Clinical Use  |
| Amatuximab is being investigated as a treatment for mesothelin over-expressing cancers [1]. Click here to link to ClinicalTrials.gov's list of amatuximab registered trials. Results from a Phase 2 trial assessing amatuximab in combination with pemetrexed and cisplatin are reported in [3]. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Amatuximab is internalised following mesothelin binding and causes antibody-dependent cellular cytotoxicity [2]. |
